New Agents in Melanoma: Nivolumab, MK-3475, Pidilizumab

Video

Dr. Atkins offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab), and weighs in on where a new agent, pidilizumab, fits into the picture.

Michael B. Atkins, MD, deputy director of the Georgetown-Lombardi Comprehensive Cancer Center, offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab) and insights as to which anti-PD1 agents are also showing the greatest promise in non-melanoma cancers. Dr. Atkins presented on phase II results of the new anti-PD1 drug pidilizumab at the 2014 ASCO Annual Meeting and weighs in on where this new agent fits into the picture.

Recent Videos
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content